CIBC World Markets’s KalVista Pharmaceuticals KALV Stock Holding History

CIBC World Markets’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-50,000	Closed	-$482K	–	755
2023 Q3	$482K	Hold	50,000	–	–	﹤0.01%	573
2023 Q2	$450K	Buy	+50,000	New	+$461K	﹤0.01%	574

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

CIBC World Markets's KALV Position: Q4 2023 in Review

CIBC World Markets sold out of KalVista Pharmaceuticals (KALV) in Q4 2023, closing a stake of 50,000 shares — an estimated $482K sold.

CIBC World Markets first reported a position in KALV in Q2 2023 and held it in 2 quarters. The position peaked at $482K in Q3 2023. 93 funds tracked by Wall St. Rank hold KALV as of Q4 2023.

CIBC World Markets reported no remaining KalVista Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
CIBC World Markets sold 50,000 KalVista Pharmaceuticals shares in Q4 2023, an estimated $482K.
CIBC World Markets first reported a position in KalVista Pharmaceuticals in Q2 2023 and held it in 2 quarters.
CIBC World Markets's KalVista Pharmaceuticals position peaked at $482K in Q3 2023.
93 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2023.

Based on CIBC World Markets's 13F filing for Q4 2023, filed 13 Feb 2024.